Bolt Projects Holdings, Inc. (BSLKW) Aandelenanalyse

Bedrijfsoverzicht

Bolt Projects Holdings, Inc. is engaged in the development and production of biomaterials products within the United States, specifically offering b-silk and xl-silk which function as biodegradable and vegan protein polymers serving as replacements for silicone elastomers in the beauty and personal care sectors. Although specific sector and industry classifications are not currently disclosed in available data, the company's operations focus on innovative material science applications targeting sustainable alternatives in consumer goods manufacturing. The enterprise operates with a workforce consisting of 14 employees, while its market capitalization and price-to-sales figures are not publicly reported, indicating a limited public valuation framework. These constraints on market cap data and the absence of traditional industry categorization suggest the company operates as a micro-cap entity, where revenue generation is driven by niche product adoption rather than broad-scale market penetration.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $3.14 million, yet it simultaneously posted a net income loss of $24.279 million and an EBITDA of $-21.1 million. The substantial disparity between the positive revenue of $3.14 million and the significant net income deficit reveals a highly leveraged cost structure where operating expenses and losses far outweigh gross earnings. Despite the negative net income, the firm generated positive free cash flow of $2.13 million, which provides a degree of financial flexibility by allowing operations to continue without immediate reliance on external equity financing. The balance sheet presents a complex picture with total cash reserves of $4.77 million against total debt obligations of $12.91 million, indicating that liquid assets are insufficient to cover total liabilities without additional capital injection. While the debt-to-equity ratio is not explicitly quantified in the available data, the negative price-to-book ratio of -0.00 and the current ratio of 0.69 suggest a balance sheet under significant financial stress regarding short-term liquidity. The current ratio of 0.69 indicates that for every dollar of current liabilities, the company holds only $0.69 in current assets, pointing to potential liquidity challenges in meeting short-term obligations. Furthermore, the return on equity is not available for calculation, while the return on assets stands at -97.5%, revealing that the company's asset base is generating substantial value destruction relative to its size.

Waarderingsbeoordeling

Trailing price-to-earnings (P/E) and forward P/E ratios are not available due to the negative earnings history, which prevents the calculation of traditional valuation multiples based on profitability. The price-to-book ratio is recorded at -0.00, a metric that typically indicates the company's market value is below its book value or that the company is insolvent, suggesting a deep discount or market skepticism regarding asset recoverability. Since the P/E and forward P/E metrics are unavailable, alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not calculable from the provided data, leaving investors without standard comparative valuation anchors. The stock traded within a narrow 52-week range with a high of $0.01 and a low of $0.01, meaning the current trading price sits effectively at the floor of its one-year trading range. The beta coefficient of 0.33 indicates that the stock's price volatility is significantly lower than the broader market, suggesting the asset price is less sensitive to general market movements despite its financial distress.

Growth & Income

The company experienced a revenue growth rate of 7300.0% year-over-year, while earnings growth is not applicable due to the absence of positive net income in the current period. This divergence, where revenue expands dramatically but earnings remain deeply negative, implies that top-line growth is being consumed entirely by operating losses, fixed cost structures, or one-time charges rather than improving profitability. The company does not pay a dividend, evidenced by the absence of a dividend yield and payout ratio, which means all available cash flows and earnings are theoretically available for reinvestment or debt servicing rather than shareholder distributions. Consequently, the growth and income profile is characterized by high revenue expansion that has not yet translated into shareholder returns, with the firm relying on organic growth in biomaterials rather than income generation or dividend payments to attract capital.